The American Cancer Society and the National Palliative Care Research Center (NPCRC) are awarding $1.5 million in research grants to researchers at ten institutions for studies aimed at reducing suffering for seriously ill patients and their family caregivers. The studies will be conducted over the next two years.
In more than a third of women with epilepsy, seizures fluctuate across the menstrual cycle, due in part to continually fluctuating effects of estrogen on the neural circuitry in the hippocampus, a region of the brain involved in learning and memory – and in epileptic seizures.
GlaxoSmithKline (GSK) and The Wellcome Trust today announced a collaboration to develop a new class of antibacterial to combat the rise of certain drug-resistant hospital-acquired infections, including those that lead to pneumonia.
A new study from the University of Michigan Health System suggests that a compound in green tea may provide therapeutic benefits to people with rheumatoid arthritis.
The Yale Child Study Center has been awarded the Autism Center of Excellence status by the National Institutes of Health. This highly competitive and prestigious award comes with $7.5 million of direct funding over five years to the Autism Program led by Ami Klin.
A Johns Hopkins team has stopped in its tracks a form of blood cancer in mice by engineering and inactivating an enzyme, telomerase, thereby shortening the ends of chromosomes, called telomeres.
Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents.
Philip Greenland, M.D., an internationally known epidemiologist who is a 1974 graduate of the University of Rochester School of Medicine and Dentistry, will speak at the ninth annual Marvin J. Hoffman Day award ceremonies Friday, April 27, at the Medical Center.
A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.
A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.